- Artelo Biosciences, Inc. closed its underwritten public offering on **October 1, 2025**.  **[1621221_0001640334-25-001766_artl_ex993.htm:0]** **[1621221_0001640334-25-001766_artl_8k.htm:1]** 
- The offering generated approximately **$2.0 million** in aggregate gross proceeds.  **[1621221_0001640334-25-001766_artl_ex993.htm:0]** **[1621221_0001640334-25-001766_artl_8k.htm:1]** 
- The offering consisted of **441,210 shares of common stock at $4.40 per share** and **pre-funded warrants to purchase up to 13,335 shares at $4.399 per pre-funded warrant**.  **[1621221_0001640334-25-001766_artl_ex993.htm:0]** **[1621221_0001640334-25-001766_artl_8k.htm:1]** 
- The company granted the underwriters a 45-day option to purchase up to an additional **68,181 shares of common stock**.  **[1621221_0001640334-25-001766_artl_ex993.htm:0]** **[1621221_0001640334-25-001766_artl_8k.htm:1]** 
- Net proceeds from the offering are intended to advance product candidates through preclinical and clinical development, and for working capital and general corporate purposes.  **[1621221_0001640334-25-001766_artl_8k.htm:1]**

ARTELO BIOSCIENCES (ARTL)